Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC34A2 | O95436 | 11/20 | 0.55 |
| ▸ | ADCYAP1R1 | P41586 | 5/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL267084 | 1.00 | SLC34A2 (0.55) | SLC34A2ADCYAP1R1LMNAGAAMAPT | |
| SCHEMBL267083 | 1.00 | SLC34A2 (0.55) | SLC34A2ADCYAP1R1LMNAGAAMAPT | |
| SCHEMBL266258 | 0.91 | SLC34A2 (0.60) | SLC34A2ADCYAP1R1 | |
| SCHEMBL266259 | 0.91 | SLC34A2 (0.60) | SLC34A2ADCYAP1R1 | |
| SCHEMBL274446 | 0.91 | SLC34A2 (0.60) | SLC34A2ADCYAP1R1 | |
| SCHEMBL265976 | 0.89 | SLC34A2 (0.49) | SLC34A2ADCYAP1R1LMNAGAAMAPT | |
| SCHEMBL273921 | 0.89 | SLC34A2 (0.65) | SLC34A2ADCYAP1R1 | |
| SCHEMBL265977 | 0.89 | SLC34A2 (0.49) | SLC34A2ADCYAP1R1LMNAGAAMAPT | |
| SCHEMBL265943 | 0.89 | SLC34A2 (0.65) | SLC34A2ADCYAP1R1 | |
| SCHEMBL273728 | 0.89 | SLC34A2 (0.49) | SLC34A2ADCYAP1R1LMNAGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115851-A1 | COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-05-10 | — | — | US | disclosed |
| US-20120115851-A1 | COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-05-10 | — | — | US | disclosed |
| US-8134015-B2 | Compound inhibiting in vivo phosphorous transport and medicine containing the same | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| US-8134015-B2 | Compound inhibiting in vivo phosphorous transport and medicine containing the same | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115851-A1 | COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME | SLC34A1, SLC34A2, SLC20A2 | SLC34A2 2/4885ADCYAP1R1 1219/4885LMNA 1925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.